IDiyas

For the Inventor, By the Inventor

Cupertino, CA, United States of America

Peter J Schatz

USPTO Granted Patents = 31 


Average Co-Inventor Count = 3.5

ph-index = 22

Forward Citations = 2,347(Granted Patents)


Location History:

  • Los Altos, CA (US) (1993)
  • Mountain View, CA (US) (1994 - 2012)
  • Cupertino, CA (US) (2004 - 2014)

Company Filing History:

goldMedal11 out of 88 
 
Affymax Technologies, N.v.
 patents
silverMedal8 out of 23 
 
Affymax, Inc.
 patents
bronzeMedal6 out of 1,168 
 
Glaxo Group Limited
 patents
4. 3 out of 281 
 
Glaxo Wellcome Inc.
 patents
5. 2 out of 2,198 
 
Smithkline Beecham Corporation
 patents
6. 1 out of 356 
 
Glaxosmithkline LLC
 patents

Years Active: 1993-2014

Loading Chart...
Loading Chart...
31 patents (USPTO):
1. 8729030 - Peptides that bind to the erythropoietin receptor (2014-05-20),
2. 8304391 - Peptides that bind to the erythropoietin receptor (2012-11-06),
3. 8227422 - Peptides and compounds that bind to a receptor (2012-07-24),
4. 7855175 - Peptides that bind to the erythropoietin receptor (2010-12-21),
5. 7528104 - Peptides that bind to the erythropoietin receptor (2009-05-05),
6. 7414105 - Peptides that bind to the erythropoietin receptor (2008-08-19),
7. 7091311 - Peptides and compounds that bind to a receptor (2006-08-15),
8. 7084245 - Peptides that bind to the erythropoietin receptor (2006-08-01),
9. 6716811 - Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses (2004-04-06),
10. 6506362 - Labeled compounds that bind to a thrombopoietin receptor (2003-01-14),
11. 6465430 - Peptides and compounds that bind to a thrombopoietin receptor (2002-10-15),
12. 6410245 - Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions (2002-06-25),
13. 6309842 - Use of modified tethers in screening compound libraries (2001-10-30),
14. 6265552 - Biotinylation of proteins (2001-07-24),
15. 6251864 - Peptides and compounds that bind to a receptor (2001-06-26),

Title: Innovations of Peter J Schatz in Biotechnology

Introduction

Peter J Schatz is a renowned inventor based in Cupertino, California, with an impressive portfolio of 31 patents. His innovative work primarily focuses on peptide compounds and their therapeutic applications, particularly in relation to the erythropoietin receptor (EPO-R).

Latest Patents

Among his most notable contributions are his patents related to peptides that bind to the erythropoietin receptor. These inventions detail peptide compounds that act as agonists of EPO-R, providing promising therapeutic methods to treat disorders linked to insufficient or defective red blood cell production. Additionally, he has developed pharmaceutical compositions that comprise these peptide compounds, thereby enhancing treatment options in the medical field.

Career Highlights

Throughout his career, Peter has worked with prestigious companies in the biotechnology sector, including Affymax Technologies, N.V. and Affymax, Inc. His tenure at these organizations has allowed him to significantly contribute to advancements in biopharmaceuticals, showcasing his commitment to medical innovation.

Collaborations

Peter J Schatz has collaborated with notable professionals in the field, including Ronald W Barrett and Christian M Gates. These partnerships have likely facilitated the exchange of ideas and accelerated the development of groundbreaking inventions.

Conclusion

In summary, Peter J Schatz stands out as an influential figure in biotechnology, with his numerous patents highlighting his contributions to improving healthcare through innovative peptide therapeutics. His work continues to pave the way for advancements in treating various blood-related disorders, benefiting countless individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…